Development of Cell and Gene Therapies for Clinical Use in the US and
EU: Summary of Regulatory Guidelines

Anand      Rotte

doi:10.2174/0115665232306205240419091414

Note! Please note that this article is currently in the "Article in Press" stage and is not the final "Version of record". While it has been accepted, copy-edited, and formatted, however, it is still undergoing proofreading and corrections by the authors. Therefore, the text may still change before the final publication. Although "Articles in Press" may not have all bibliographic details available, the DOI and the year of online publication can still be used to cite them. The article title, DOI, publication year, and author(s) should all be included in the citation format. Once the final "Version of record" becomes available the "Article in Press" will be replaced by that.

Abstract

Recent decades have seen advancements in the management and treatment of difficult-- to-treat diseases such as cancer. A special class of therapeutics called cell and gene therapy has been introduced in the past 10 years. Cell and gene therapy products have strengthened the treatment options for life-threatening diseases with unmet clinical needs and also provided the possibility of a potential cure for the disease in some of the patients. Cell and gene therapy products are gaining recognition, and the interest in clinical development of cell and gene therapy products is increasing. Moreover, as the class of cell and gene therapy products is relatively new, there is a limited regulatory experience in the development, and the developers of the cell and gene therapy products can often be puzzled with an array of questions on regulations. The current review intends to provide a basic understanding of regulatory guidelines from the FDA and EMA that are applicable to cell and gene therapy products. Essentials such as which office is responsible for the evaluation of applications, which regulatory class/pathway is appropriate for development, and what are the quality, nonclinical and clinical studies that are needed to support the application are discussed in the article. In addition, a summary of regulatory designations and the post-approval requirements, such as Risk Evaluation and Mitigation Strategies (REMS) and long-term follow- up, is included in the article. Developers (referred to as ‘sponsors’ in this article) of cell and gene therapies can use the respective guidance documents and other specific review articles cited in this review for detailed information on the topics.

[1]
Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: The beginning of the end of cancer? BMC Med  2016; 14(1): 73.
 [http://dx.doi.org/10.1186/s12916-016-0623-5] [PMID: 27151159]

[2]
Lazzari C, Karachaliou N, Bulotta A, et al. Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: Is this the beginning of the end for cancer? Ther Adv Med Oncol  2018; 10: 1758835918762094.
 [http://dx.doi.org/10.1177/1758835918762094] [PMID: 29662546]

[3]
Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res  2019; 38(1): 255.
 [http://dx.doi.org/10.1186/s13046-019-1259-z] [PMID: 31196207]

[4]
Toh HC. Cancer immunotherapy—the end of the beginning. Chin Clin Oncol  2018; 7(2): 12.
 [http://dx.doi.org/10.21037/cco.2018.04.03] [PMID: 29764157]

[5]
Rotte A. Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: Editorial commentary. Ann Transl Med  2023; 11(5): 227.
 [http://dx.doi.org/10.21037/atm-22-6564] [PMID: 37007583]

[6]
Whiteside TL, Demaria S, Ruiz RME, Zarour HM, Melero I. Emerging opportunities and challenges in cancer immunotherapy. Clin Cancer Res  2016; 22(8): 1845-55.
 [http://dx.doi.org/10.1158/1078-0432.CCR-16-0049] [PMID: 27084738]

[7]
Christofi T, Baritaki S, Falzone L, Libra M, Zaravinos A. Current perspectives in cancer immunotherapy. Cancers  2019; 11(10): 1472.
 [http://dx.doi.org/10.3390/cancers11101472] [PMID: 31575023]

[8]
Rotte A, Sahasranaman S, Budha N. Targeting TIGIT for immunotherapy of cancer: Update on clinical development. Biomedicines  2021; 9(9): 1277.
 [http://dx.doi.org/10.3390/biomedicines9091277] [PMID: 34572463]

[9]
Liu M, Guo F. Recent updates on cancer immunotherapy. Precis Clin Med  2018; 1(2): 65-74.
 [http://dx.doi.org/10.1093/pcmedi/pby011] [PMID: 30687562]

[10]
Lemaire V, Shemesh CS, Rotte A. Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations. J Exp Clin Cancer Res  2021; 40(1): 311.
 [http://dx.doi.org/10.1186/s13046-021-02111-5] [PMID: 34598713]

[11]
Singh P, Rotte A, Golsorkhi AA, Girish S. Optimizing outcomes and managing adverse events in locally advanced or metastatic urothelial cancer: A clinical pharmacology perspective. Expert Rev Clin Pharmacol  2023; 16(6): 533-48.
 [http://dx.doi.org/10.1080/17512433.2023.2219446] [PMID: 37282597]

[12]
Rohaan MW, Wilgenhof S, Haanen JBAG. Adoptive cellular therapies: The current landscape. Virchows Arch  2019; 474(4): 449-61.
 [http://dx.doi.org/10.1007/s00428-018-2484-0] [PMID: 30470934]

[13]
Hoang DM, Pham PT, Bach TQ, et al. Stem cell-based therapy for human diseases. Signal Transduct Target Ther  2022; 7(1): 272.
 [http://dx.doi.org/10.1038/s41392-022-01134-4] [PMID: 35933430]

[14]
Frigault M, Rotte A, Ansari A, Gliner B, Heery C, Shah B. Dose fractionation of CAR-T cells. A systematic review of clinical outcomes. J Exp Clin Cancer Res  2023; 42(1): 11.
 [http://dx.doi.org/10.1186/s13046-022-02540-w] [PMID: 36627710]

[15]
Rotte A, Frigault MJ, Ansari A, Gliner B, Heery C, Shah B. Dose–response correlation for CAR-T cells: A systematic review of clinical studies. J Immunother Cancer  2022; 10(12): e005678.
 [http://dx.doi.org/10.1136/jitc-2022-005678] [PMID: 36549782]

[16]
Rotte A, Heery C, Gliner B, Tice D, Hilbert DM. BCMA targeting CAR T cells using a novel D-domain binder for multiple myeloma: Clinical development update. Immuno Oncology Insights  2022; 3(1): 13-24.
 [http://dx.doi.org/10.18609/ioi.2022.003]

[17]
Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J  2021; 11(4): 69.
 [http://dx.doi.org/10.1038/s41408-021-00459-7] [PMID: 33824268]

[18]
Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol  2020; 17(3): 147-67.
 [http://dx.doi.org/10.1038/s41571-019-0297-y] [PMID: 31848460]

[19]
Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics  2016; 3: 16011.
 [http://dx.doi.org/10.1038/mto.2016.11] [PMID: 27626062]

[20]
Mohanty R, Chowdhury C, Arega S, Sen P, Ganguly P, Ganguly N. CAR T cell therapy: A new era for cancer treatment (Review). Oncol Rep  2019; 42(6): 2183-95.
 [http://dx.doi.org/10.3892/or.2019.7335] [PMID: 31578576]

[21]
Rath JA, Arber C. Engineering strategies to enhance TCR-based adoptive T cell therapy. Cells  2020; 9(6): 1485.
 [http://dx.doi.org/10.3390/cells9061485] [PMID: 32570906]

[22]
Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Sci Adv  2023; 9(7): eadf3700.
 [http://dx.doi.org/10.1126/sciadv.adf3700] [PMID: 36791198]

[23]
Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science  2018; 359(6372): eaan4672.
 [http://dx.doi.org/10.1126/science.aan4672] [PMID: 29326244]

[24]
Scheller EL, Krebsbach PH. Gene therapy: Design and prospects for craniofacial regeneration. J Dent Res  2009; 88(7): 585-96.
 [http://dx.doi.org/10.1177/0022034509337480] [PMID: 19641145]

[25]
Uddin F, Rudin CM, Sen T. CRISPR gene therapy: Applications, limitations, and implications for the future. Front Oncol  2020; 10: 1387.
 [http://dx.doi.org/10.3389/fonc.2020.01387] [PMID: 32850447]

[26]
Li T, Yang Y, Qi H, et al. CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduct Target Ther  2023; 8(1): 36.
 [http://dx.doi.org/10.1038/s41392-023-01309-7] [PMID: 36646687]

[27]
Keeler AM, ElMallah MK, Flotte TR. Gene therapy 2017: Progress and future directions. Clin Transl Sci  2017; 10(4): 242-8.
 [http://dx.doi.org/10.1111/cts.12466] [PMID: 28383804]

[28]
Munis AM. Gene therapy applications of non-human lentiviral vectors. Viruses  2020; 12(10): 1106.
 [http://dx.doi.org/10.3390/v12101106] [PMID: 33003635]

[29]
Jie XL, Ying HX, Ping ZK, Lian JC, Juan LJ. CRISPR-Cas9: A new and promising player in gene therapy. J Med Genet  2015; 52(5): 289-96.
 [http://dx.doi.org/10.1136/jmedgenet-2014-102968] [PMID: 25713109]

[30]
Huang J, Zhou Y, Li J, Lu A, Liang C. CRISPR/Cas systems: Delivery and application in gene therapy. Front Bioeng Biotechnol  2022; 10: 942325.
 [http://dx.doi.org/10.3389/fbioe.2022.942325] [PMID: 36483767]

[31]
Ghaleh GHE, Bolandian M, Dorostkar R, Jafari A, Pour MF. Concise review on optimized methods in production and transduction of lentiviral vectors in order to facilitate immunotherapy and gene therapy. Biomed Pharmacother  2020; 128: 110276.
 [http://dx.doi.org/10.1016/j.biopha.2020.110276] [PMID: 32502836]

[32]
Manilla P, Rebello T, Afable C, et al. Regulatory considerations for novel gene therapy products: A review of the process leading to the first clinical lentiviral vector. Hum Gene Ther  2005; 16(1): 17-25.
 [http://dx.doi.org/10.1089/hum.2005.16.17] [PMID: 15703485]

[33]
Ma C-C, Wang Z-L, Xu T, et al. The approved gene therapy drugs worldwide: From 1998 to 2019. Biotechnology Adv  2020; 40: 107502.

[34]
Takefman D, Bryan W. The state of gene therapies: the FDA perspective. Mol Ther  2012; 20(5): 877-8.
 [http://dx.doi.org/10.1038/mt.2012.51] [PMID: 22549801]

[35]
Elverum K, Whitman M. Delivering cellular and gene therapies to patients: Solutions for realizing the potential of the next generation of medicine. Gene Ther  2020; 27(12): 537-44.
 [http://dx.doi.org/10.1038/s41434-019-0074-7] [PMID: 31024072]

[36]
Marks P. The FDA’s regulatory framework for chimeric antigen receptor-T cell therapies. Clin Transl Sci  2019; 12(5): 428-30.
 [http://dx.doi.org/10.1111/cts.12666] [PMID: 31328862]

[37]
Eisenman D, Swindle S. FDA guidance on shedding and environmental impact in clinical trials involving gene therapy products. Appl Biosaf  2022; 27(3): 191-7.
 [http://dx.doi.org/10.1089/apb.2022.0020] [PMID: 36779200]

[38]
Locke FL, Davila ML. Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapy. Expert Opin Biol Ther  2017; 17(6): 659-61.
 [http://dx.doi.org/10.1080/14712598.2017.1322953] [PMID: 28454503]

[39]
Wills CA, Drago D, Pietrusko RG. Clinical holds for cell and gene therapy trials: Risks, impact, and lessons learned. Mol Ther Methods Clin Dev  2023; 31: 101125.
 [http://dx.doi.org/10.1016/j.omtm.2023.101125] [PMID: 37886603]

[40]
Dasgupta A, Herzegh K, Spencer HT, Doering C, Day E, Swaney WP. Regulatory framework for academic investigator-sponsored investigational new drug development of cell and gene therapies in the USA. Curr Stem Cell Rep  2021; 7(4): 129-39.
 [http://dx.doi.org/10.1007/s40778-021-00196-4] [PMID: 34608428]

[41]
Galaro KA, Saeui C. FDA perspective on the preclinical development of cell-based immunotherapies. Cell Gene Ther Insights  2020; 6(9): 1381-90.
 [http://dx.doi.org/10.18609/cgti.2020.148]

[42]
Approved cellular and gene therapy products (Internet). 2023. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products

[43]
Director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies (Internet). 2019. Available from: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-peter-marks-md-phd-director-center-biologics

[44]
Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet  2023; 402(10416): 2034-44.
 [http://dx.doi.org/10.1016/S0140-6736(23)01126-1] [PMID: 37748491]

[45]
Zmievskaya E, Valiullina A, Ganeeva I, Petukhov A, Rizvanov A, Bulatov E. Application of CAR-T cell therapy beyond oncology: Autoimmune diseases and viral infections. Biomedicines  2021; 9(1): 59.
 [http://dx.doi.org/10.3390/biomedicines9010059] [PMID: 33435454]

[46]
Papaioannou I, Owen JS, Muñoz YRJ. Clinical applications of gene therapy for rare diseases: A review. Int J Exp Pathol  2023; 104(4): 154-76.
 [http://dx.doi.org/10.1111/iep.12478] [PMID: 37177842]

[47]
Bueren JA, Auricchio A. Advances and challenges in the development of gene therapy medicinal products for rare diseases. Hum Gene Ther  2023; 34(17-18): 763-75.
 [http://dx.doi.org/10.1089/hum.2023.152] [PMID: 37694572]

[48]
Kalland ME, Boirazian PT, Palomo GM, et al. Advancing rare disease treatment: EMA’s decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation. Gene Ther  2024; 2024.
 [http://dx.doi.org/10.1038/s41434-024-00446-0] [PMID: 38480914]

[49]
Human gene therapy for rare diseases. Research CfBEa 2020.

[50]
Kohler M. Regulatory pathways in the European Union. MAbs  2011; 3(3): 241-2.
 [http://dx.doi.org/10.4161/mabs.3.3.15474] [PMID: 21487236]

[51]
Fontana SLI. A regulatory risk-based approach to ATMP/CGT development: Integrating scientific challenges with current regulatory expectations. Front Med  2022; 9: 855100.
 [http://dx.doi.org/10.3389/fmed.2022.855100] [PMID: 35646952]

[52]
Formal meetings between the FDA and sponsors or applicants. CDER, CBER 2009.

[53]
M4 organization of the common technical document for the registration of pharmaceuticals for human use guidance for industry. (CDER) CfDEaR, (CBER) CfBEaR 2017.

[54]
Guidance-for-industry-providing-regulatory-submissions-in-electronic-format-—-human-pharmaceutical-product-applications-and-related-submissions-using-the-eCTD. (CDER) CfDEaR, (CBER) CfBEaR 2008.

[55]
Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs). Research CfBEa 2020.

[56]
Manufacturing Changes FDA. Manufacturing changes and comparability for human cellular and gene therapy products (Draft guidance). Research CfBEa 2023.

[57]
M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. (CDER) CfDEaR, (CBER) CfBEaR 2010.

[58]
ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. European Medicines Agency 2009.

[59]
S12 nonclinical biodistribution considerations for gene therapy products guidance for industry. (CDER) CfDEaR, (CBER) CfBEaR 2023.

[60]
Guideline on the Non-Clinical Studies Required Before First Clinical Use of Gene Therapy Medicinal Products. Use CftMPfH 2008.

[61]
Moffit JS, Blanset DL, Lynch JL, et al. Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies. Hum Gene Ther  2022; 33(21-22): hum.2022.090.
 [http://dx.doi.org/10.1089/hum.2022.090] [PMID: 35994386]

[62]
Gee AP. How to design a cell or gene therapy clinical trial: Advice from the FDA. Mol Ther  2013; 21(9): 1639-40.
 [http://dx.doi.org/10.1038/mt.2013.172] [PMID: 24008615]

[63]
Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products. Research CfBEa 2015.

[64]
ICH guideline E8 (R1) on general considerations for clinical studies. (CHMP) CfHMP 2021.

[65]
E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1). (CDER) CfDEaR, (CBER) CfBEaR 2018.

[66]
Establishment and Operation of Clinical Trial Data Monitoring Committees. (CBER) CfBEaR, (CDER) CfDEaR, (CDRH) CfDaRH 2006.

[67]
Pacud ZŻ, Lenarczyk G. Clinical trial data transparency in the EU: Is the new clinical trials regulation a game-changer? IIC Int Rev Ind Prop Copyr Law  2023; 54(5): 732-63.
 [http://dx.doi.org/10.1007/s40319-023-01329-4] [PMID: 37215361]

[68]
Drago D, Campbell FB, Wonnacott K, Barrett D, Ndu A. Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs. Mol Ther Methods Clin Dev  2021; 21: 524-9.
 [http://dx.doi.org/10.1016/j.omtm.2021.04.001] [PMID: 33997101]

[69]
Guidance for Industry: Expedited Programs for Serious Conditions. (CDER) CfDEaR, (CBER) CfBEaR 2014.

[70]
Guidance for industry: Expedited programs for regenerative medicine therapies for serious conditions. (CBER) CfBEaR 2019.

[71]
PRIME: priority medicines 2023. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/prime-priority-medicines [cited on: 2023]

[72]
PRIME: Analysis of the first 5 years’experience. Findings, learnings and recommendations 2022.

[73]
Lomash RM, Shchelochkov O, Chandler RJ, Venditti CP, Pariser AR, Ottinger EA. Successfully navigating food and drug administration orphan drug and rare pediatric disease designations for AAV9-hPCCA gene therapy: The national institutes of health platform vector gene therapy experience. Hum Gene Ther  2023; 34(5-6): 217-27.
 [http://dx.doi.org/10.1089/hum.2022.232] [PMID: 36694456]

[74]
Long term follow up after administration of human gene therapy products. Research CfBEa 2020.

[75]
Guideline on follow-up of patients administered with gene therapy medicinal products. CHMP 2009.

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0115665232306205240419091414	Print ISSN 1566-5232
Publisher Name Bentham Science Publisher	Online ISSN 1875-5631

Current Gene Therapy

Development of Cell and Gene Therapies for Clinical Use in the US and EU: Summary of Regulatory Guidelines

Abstract

Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)

Current Gene Therapy

Development of Cell and Gene Therapies for Clinical Use in the US and EU: Summary of Regulatory Guidelines

Abstract Play Pause

Call for Papers in Thematic Issues

Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)

Related Journals

Related Books

Abstract